I recently came across this video, in which at 5:40 into the video, Dr. Pierre Kory, president of the FLCCC (Frontline COVID-19 Critical Care Alliance) tells members of the US Senate Committee on Homeland Security and Governmental Affairs that ivermectin, an anti-parasitic drug that has been in use for about 40 years, is having amazing results in regards to covid19 infection prevention.
FLCCC describes itself as a group formed by "leading critical care specialists in March 2020...a non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve the outcomes for patients ill with the disease." Its hard to find much in the news about them. They have about 6500 followers on Facebook and about 3,000 on Twitter.
In the document that Kory gave to the US Senate, Kory cites Dr. Hector Carvallo (who ran the trial mentioned above) 4 times, linking the same 2 webpages twice. Neither link mentions the incredible figures that Kory provided on the Senate floor.
So far, I have asked several people on Twitter - many claiming to be doctors - who posted supportive statements regarding Kory's Senate appearance, if they could show me the trial that he referenced. None were able to provide me the link. I emailed FLCCC and they sent me a PDF of the trial, which helped me find a link to it, seen here. It was published in an obscure Open Access journal for about $1800, which usually is not a good sign.
What definitely is not a good sign is that FLCCC is still using the retracted pre-print study from the infamous Surgisphere scandal, seen in citation 178 here (it has since been removed, with no mention of their mistake) in a document released 12/03/2020, long after the scandal was revealed. The FLCCC website makes no mention of the Surgisphere scandal, despite the main study that Kory went over in the Senate being from Argentina and "the policy decisions in Latin-America have been largely based on the analysis presented in a pre-print" of the Surgisphere-tainted study and has "been downloaded 15,655 times, its abstract has been viewed 89,895 times (as of May 28, 2020)" according to ISGlobal.
Dr. Carlos Chaccour of ISGlobal, who has an extensive interest in ivermectin, noticed a lot of abnormalities with the study and a rapid push to use ivermectin in South America. According to The Guardian, Chaccour "wrote in an editorial in which he was lead author, published on 16 April...(and) sent the lead researcher on the preprint paper an email with some questions and concerns about the data, which were forwarded to a co-author of the paper, the Surgisphere founder and chief executive, Dr Sapan Desai.
Instead of answering his questions about the data, Chaccour says, Desai flattered him and spoke enthusiastically about potential collaboration."
Sepan Desai, Amit Patel, and Mandeep Mehra, the 3 men behind the fraudulent study indicating ivermectin is an effective tool for covid, are the same persons involved in the "monumental fraud" that was published in The Lancet and NEJM regarding HCQ.
From BMJ: "Since this research had been divulged only as a preprint, no journal had to issue an EOC followed by an official retraction. The legacy of this fraudulent research is still alive and will continue to cause harm through false sense of security, possible side effects and shortage of the drug for its appropriate applications."
According to Science Magazine: "Normally co-authors of high-profile papers share subject area expertise or have clear professional ties, says Jerome Kassirer, chief editor of NEJM during the 1990s. He calls the collaboration of the apparently disparate individuals “completely bizarre,” and a red flag that the studies warranted intensive scrutiny that the journals failed to provide."
"Journal disclosures, however, also indicate Mehra received compensation from Triple-Gene, a gene therapy company Patel co-founded to develop cardiovascular treatments."
Update 12/21/20: FLCCC finally fixed the Surgisphere citation, but just in case they lie and say they never cited Dr. Mehra, here's a screenshot. Also, they never got back to me when I emailed them about the mistake, which seems shady to me. I would thank someone if they pointed out a major mistake on my website, but that's just me. They did manage to question my credentials on Twitter though.
12/22/20: Apparently the Carvallo study with 1,195 participants was linked to on a manuscript, which was linked to on the Senate document. Weird to hide their favorite study behind another link and not have it on the main document page. Interestingly, it says the sample size is 229 on the chart for the 1,195 person study.